MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study

What Was Tested

This randomized controlled trial paper looks at Glucagon and Cotadutide.

MEDI0382 is a balanced glucagon-like peptide-1/glucagon receptor dual agonist under development for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis.

The primary objective was to assess the safety of MEDI0382 in healthy subjects.

The primary objective was safety and tolerability.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

All subjects were followed for up to 28 days.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Glucagon, giving a reference point.

The timeline in the abstract includes 28 days.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Half-Life, Healthy Volunteers, Hypoglycemic Agents, Peptides and Receptors, Glucagon.

The authors tagged it with the keywords Phase 1, drug safety and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon and Cotadutide over 28 days.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (British journal of clinical pharmacology), a journal based in England.

More context: the Glucagon compound page and the Cotadutide compound page, all human trials.